Scientific article
Comment
OA Policy
English

Is Higher Dose of Inhaled Treprostinil Truly Superior to Lower Dose of Inhaled Treprostinil in Patients With Pulmonary Hypertension Associated With Interstitial Lung Diseases ?

Published inChest, vol. 165, no. 5, e161
Publication date2024-05
First online date2024-05
Abstract

Comment on : Nathan SD, Deng C, King CS, DuBrock HM, Elwing J, Rajagopal S, Rischard F, Sahay S, Broderick M, Shen E, Smith P, Tapson VF, Waxman AB. Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes. Chest. 2023 Feb;163(2):398-406. doi: 10.1016/j.chest.2022.09.007. Epub 2022 Sep 15. PMID: 36115497; PMCID: PMC10083130.

Keywords
  • Humans
  • Epoprostenol / analogs & derivatives
  • Epoprostenol / administration & dosage
  • Lung Diseases, Interstitial / drug therapy
  • Lung Diseases, Interstitial / complications
  • Hypertension, Pulmonary / drug therapy
  • Administration, Inhalation
  • Antihypertensive Agents / administration & dosage
  • Antihypertensive Agents / therapeutic use
  • Dose-Response Relationship, Drug
Citation (ISO format)
GENECAND, Léon et al. Is Higher Dose of Inhaled Treprostinil Truly Superior to Lower Dose of Inhaled Treprostinil in Patients With Pulmonary Hypertension Associated With Interstitial Lung Diseases ? In: Chest, 2024, vol. 165, n° 5, p. e161. doi: 10.1016/j.chest.2023.12.032
Main files (1)
Article (Published version)
Identifiers
Journal ISSN0012-3692
9views
48downloads

Technical informations

Creation09/12/2025 10:44:29
First validation15/01/2026 16:49:45
Update15/01/2026 16:49:45
Status update15/01/2026 16:49:45
Last indexation15/01/2026 16:49:46
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack